We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+62.1%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$4.18B
AUM Growth
+$1.19B
(+40%)
Cap. Flow
+$115M
Cap. Flow
% of AUM
2.75%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
89
New
15
Increased
28
Reduced
14
Closed
24
Top Buys
| 1 |
Biogen
BIIB
|
+$127M |
| 2 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$72.2M |
| 3 |
Boston Scientific
BSX
|
+$68.3M |
| 4 |
Aprea Therapeutics
APRE
|
+$62.5M |
| 5 |
UnitedHealth
UNH
|
+$52.9M |
Top Sells
| 1 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$155M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$114M |
| 3 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$87.2M |
| 4 |
CELG
Celgene Corp
CELG
|
+$55.9M |
| 5 |
WMGI
Wright Medical Group Inc
WMGI
|
+$49.6M |
Sector Composition
| 1 | Healthcare | 98.47% |
| 2 | Industrials | 0.33% |
| 3 | Technology | 0% |
| 4 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $293M | 7.01% |
4,709,498
-71,400
| -1% | -$3.39M |
|
|
ALLK
2
DELISTED
Allakos
ALLK
| $289M | 6.92% |
3,033,526
-43,602
| -1% | -$3.83M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $246M | 5.87% |
25,209,964
+2,419,830
| +11% | +$22.2M |
|
4
Fate Therapeutics
FATE
$336M
| $220M | 5.25% |
11,216,809
| – | – |
|
|
EPZM
5
DELISTED
Epizyme, Inc
EPZM
| $215M | 5.15% |
8,746,033
+109,100
| +1% | +$1.62M |
|
6
argenx
ARGX
$54.1B
| $185M | 4.43% |
1,153,232
+72,800
| +7% | +$9.85M |
|
7
uniQure
QURE
$2.78B
| $183M | 4.38% |
2,553,325
+143,200
| +6% | +$7.86M |
|
|
PRNB
8
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $149M | 3.57% |
2,722,388
+1,932,382
| +245% | +$72.2M |
|
|
9
Biogen
BIIB
$28.9B
| $136M | 3.25% |
+457,500
| New | +$127M |
|
|
IGMS
10
DELISTED
IGM Biosciences
IGMS
| $120M | 2.87% |
3,144,000
| – | – |
|
11
Bristol-Myers Squibb
BMY
$119B
| $116M | 2.76% |
1,800,800
-451,800
| -20% | -$25.9M |
|
|
NVRO
12
DELISTED
NEVRO CORP.
NVRO
| $110M | 2.64% |
939,164
+295,300
| +46% | +$29.2M |
|
|
FTSV
13
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $109M | 2.61% |
2,770,842
+1,143,344
| +70% | +$18.4M |
|
|
14
Aprea Therapeutics
APRE
$8.82M
| $104M | 2.49% |
+113,436
| New | +$62.5M |
|
15
Regenxbio
RGNX
$621M
| $103M | 2.46% |
2,508,386
+145,900
| +6% | +$5.76M |
|
16
Centene
CNC
$33B
| $97.6M | 2.33% |
1,552,598
+742,100
| +92% | +$40.3M |
|
|
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
| $80.4M | 1.92% |
2,129,100
+51,400
| +2% | +$1.92M |
|
18
Atara Biotherapeutics
ATRA
$76.6M
| $76.6M | 1.83% |
185,943
+5,154
| +3% | +$1.78M |
|
|
IMGN
19
DELISTED
Immunogen Inc
IMGN
| $74.7M | 1.79% |
14,639,960
+23,400
| +0.2% | +$79.4K |
|
|
20
Boston Scientific
BSX
$64.6B
| $73.8M | 1.76% |
+1,631,200
| New | +$68.3M |
|
21
Tandem Diabetes Care
TNDM
$1.07B
| $69.9M | 1.67% |
1,172,232
+11,831
| +1% | +$730K |
|
|
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $63.9M | 1.53% |
+3,237,700
| New | +$51.8M |
|
23
Krystal Biotech
KRYS
$10.2B
| $60.4M | 1.44% |
1,090,200
+11,900
| +1% | +$584K |
|
|
24
UnitedHealth
UNH
$383B
| $59.7M | 1.43% |
203,100
+202,129
| +20,817% | +$52.9M |
|
25
Novartis
NVS
$289B
| $54.3M | 1.3% |
+573,100
| New | +$51.4M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO